In conclusion, entrectinib has demonstrated durable overall and intracranial responses with longer follow-up in patients with ROS1 fusion-positive NSCLC, with and without baseline CNS metastases, including those who had received it as a first-line treatment. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.